GlassScriptPhysician profile
Stephanie Lynne Shaeffer
NPI 1215415302
$2,744.95
in general payments reported to CMS, 2019-2025
12 companies · $527 in 2025
The $527 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,218 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551 · Travel and Lodging: $1,032 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.19 |
| Travel and Lodging | $1,031.78 |
| Education | $161.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,277.51 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $396.58 | 2024-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $394.04 | 2024 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $281.12 | 2024-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $96.70 | 2024-2025 | |
| Philips North America LLC | $83.29 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Baxter Healthcare | $59.47 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Glaxosmithkline, LLC. | $57.19 | 2024-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Insmed, INC. | $28.35 | 2025 | Arikayce |
| Merck Sharp & Dohme LLC | $28.10 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.41 | 2024 | Ofev |
| Regeneron Healthcare Solutions, INC. | $18.19 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Shaeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.